As of Q4'25, META's operating expenses show R&D Expenses at USD 17.1B and SG&A Expenses at USD 7.1B, marking the highest levels for both categories in the period analyzed. This latest data point highlights a significant increase in spending, particularly in R&D, which has more than doubled since Q1'23. From Q1'23 to Q4'25, the chart reveals a pronounced upward trend in R&D Expenses, accelerating notably from Q2'25 onwards, while SG&A Expenses display more volatility but also end at a peak. R&D Expenses rose steadily from USD 9.4B in Q1'23, with sharp growth after Q2'25, suggesting increased investment in innovation or product development. In contrast, SG&A Expenses fluctuated, dipping as low as USD 4B in Q4'24 before rebounding to USD 7.1B in Q4'25, indicating variable administrative and sales costs over the period.